Organogenesis Holdings Inc. provided earnings guidance for the Fiscal Year 2023. For the year, the company expects Net revenue between $454 million and $466 million, representing an increase of approximately 1% to 3% year-over-year, as compared to net revenue of $450.9 million for the year ended December 31, 2022. Net income between $3 million and $11 million and adjusted net income between $8 million and $16 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | +1.52% | -3.61% | -34.72% |
05-13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
05-10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.72% | 354M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.57% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023